CVS Health shares outperformed the broader market in the most recent session, gaining 2.82% after closing at $74.03. This rebound followed a sharp intra-week sell-off that saw the stock fall nearly 15% in a single day. Volume remained elevated, with more than 11.8 million shares changing hands on the session in which it last traded at $74.74, underscoring strong investor engagement despite sectorwide weakness.

Investor sentiment turned negative when the Centers for Medicare & Medicaid Services proposed a mere 0.09% increase in Medicare Advantage payment rates for 2027, well below the 4%–6% that market participants had forecast. The surprise rate call precipitated a 14% stock decline at CVS, though this was less severe than declines exceeding 20% at some peers. The freeze in payment growth poses direct pressure on CVS’s pharmacy benefit management segment, which derives a significant portion of revenue from Medicare Advantage plans.

Despite recent volatility, twenty sell-side analysts maintain a Buy or Outperform view on CVS, with an average price target of $94.86. Bank of America recently trimmed its target from $100 to $95 but kept a Buy rating, reflecting confidence in longer-term upside. Other firms—TD Cowen, Evercore ISI and Barclays—have issued targets between $91 and $105. Meanwhile, an insider purchase by Executive Vice President Steven H. Nelson—24 shares at approximately $53.70 each—serves as a modest nod to management’s conviction in the company’s prospects.

CVS reported third-quarter revenue of $102.87 billion, topping consensus estimates of $98.85 billion, and delivered EPS of $1.60 versus $1.36 consensus. For fiscal 2025, management guided to $6.55–$6.65 in earnings per share, underpinned by a growing retail footprint and stable pharmacy benefit margins. The company also declared a quarterly dividend of $0.665 per share, equating to a 3.7% yield and reflecting a 700% payout ratio on trailing earnings, while maintaining a debt-to-equity ratio of 0.83 and a current ratio of 0.83.